瑞典隆德大学（Lund University）的一个研究小组最新的研究发现，对于正在接受他莫昔芬 （Tamoxifen）药物治疗的乳腺癌患者，每天多喝几杯散发浓浓香气的热咖啡，能够降低愈后乳腺癌复发的风险。
多年来（平均时间5年），该研究小组追踪了来自瑞典南部的600多名乳腺癌患者，其中大约300名患者接受他莫昔芬药物治疗。他莫昔芬是乳腺癌手术切除后降低癌症复发的常用药物。研究人员比较了每天喝一杯或更少咖啡，以及每天喝两杯或更多咖啡的乳腺癌患者，结果表明多喝咖啡的患者他们的乳腺癌复发几率要比喝咖啡少的患者降低一半还要多。 然而，虽然该研究表明咖啡对乳腺癌治疗的益处，但咖啡是如何发挥作用的，研究人员对此依然不得而知。不过研究人员猜测可能是由于咖啡进一步"激发"了他莫昔芬的药性，使得它治疗效果更强。
另外，隆德大学的研究人员早就发现喝咖啡与降低女性患乳腺癌的几率之间的关联。大量研究也表明咖啡中的有效成分－咖啡因－对癌细胞的生长有抑制作用。这一系列的研究结果，一定会让整天忙忙碌碌身心疲惫的都市女白领们欢心雀跃吧：咖啡，不但让我一整天精神抖擞，而且给我带来身体健康！（生物谷Bioon.com）
DOI: 10.1007/s10552-013-0169-1
Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status
Maria Simonsson, Viktoria Söderlind, Maria Henningson, Maria Hjertberg, Carsten Rose, Christian Ingvar, Helena Jernström
Purpose
Whether coffee modulates response to endocrine therapy in breast cancer patients is currently unknown. The CYP1A2 and CYP2C8 enzymes contribute to tamoxifen and caffeine metabolism. The purpose was to investigate the impact of coffee consumption on tumor characteristics and risk for early events in relation to breast cancer treatment and CYP1A2 and CYP2C8 genotypes.
Methods
Questionnaires regarding lifestyle were completed preoperatively by 634 patients in southern Sweden. CYP1A2*1F and CYP2C8*3 were genotyped. Clinical data and tumor characteristics were obtained from patients’ charts, population registries, and pathology reports. Coffee consumption was categorized as low (0–1 cups/day), moderate (2–4 cups/day), or high (5+ cups/day).
Results
The proportion of estrogen receptor negative (ER–) tumors increased with increasing coffee consumption (p trend = 0.042). Moderate to high consumption was associated with lower frequency of discordant receptor status (ER + PgR–) OR 0.38 (0.23–0.63) compared to low consumption. Median follow-up time was 4.92 (IQR 3.01–6.42) years. Tamoxifen-treated patients with ER+ tumors (n = 310) who consumed two or more cups/day had significantly decreased risk for early events compared to patients with low consumption, adjusted HR 0.40 (0.19–0.83). Low consumption combined with at least one CYP1A2*1F C-allele (n = 35) or CYP2C8*3 (n = 13) was associated with a high risk for early events in tamoxifen-treated patients compared to other tamoxifen-treated patients, adjusted HRs 3.49 (1.54–7.91) and 6.15 (2.46–15.36), respectively.
Conclusion
Moderate to high coffee consumption was associated with significantly decreased risk for early events in tamoxifen-treated patients and modified hormone receptor status. If confirmed, new recommendations regarding coffee consumption during tamoxifen treatment may be warranted.
